frontier-banner
前沿速递
首页>前沿速递>

Nature Communications | Phase I/II Study of Olaparib Combined with Tremelimumab for Recurrent BRCA-Mutated Ovarian Cancer

Nature Communications | Phase I/II Study of Olaparib Combined with Tremelimumab for Recurrent BRCA-Mutated Ovarian Cancer
--

This study reveals the synergistic potential of combining CTLA-4 inhibitors with PARP inhibitors in BRCA-mutated ovarian cancer, providing a new biomarker screening strategy to overcome immune checkpoint resistance.

 

Literature Overview

This article, "Olaparib plus tremelimumab in women with recurrent ovarian cancer and a germline BRCA1 or BRCA2 mutation: a phase I/II study," published in Nature Communications, systematically explores the safety and efficacy of combining the PARP inhibitor Olaparib with the CTLA-4 immune checkpoint inhibitor Tremelimumab for treating patients with recurrent epithelial ovarian cancer harboring germline BRCA1 or BRCA2 mutations. Through a multicenter, single-arm trial, the study evaluated tumor response rates, progression-free survival, and potential predictive biomarkers for this combination regimen in previously treated patients.

Background Knowledge

Although PARP inhibitors have demonstrated significant efficacy in BRCA-mutated ovarian cancer, acquired resistance remains a major clinical challenge. Currently, the response rates to single-agent immune checkpoint blockade (ICB) in ovarian cancer are generally low, primarily limited by the immunosuppressive characteristics of the tumor microenvironment. CTLA-4, as a critical immune checkpoint, plays a vital role in regulating T cell activation; however, its precise efficacy and optimal combination strategies in ovarian cancer remain unclear. This study aims to leverage the DNA damage repair defects and immunogenic cell death induced by PARP inhibitors to synergistically enhance the anti-tumor immune response of CTLA-4 blockade. The goal is to address the treatment dilemma in patients with platinum and PARP inhibitor resistance, while exploring novel transcriptomic biomarkers such as IFIT1B and VSTM5 to precisely identify patients who would benefit.

 

 

Research Methods and Experiments

This study employed a multicenter, open-label, single-arm Phase I/II clinical trial design, enrolling 50 patients with recurrent ovarian cancer harboring germline BRCA1 or BRCA2 mutations. The experimental framework included a dose-escalation phase (Phase I) to determine the recommended dose, followed by an expansion cohort (Phase II) to assess efficacy. Key experimental approaches included: oral administration of Olaparib combined with intravenous Tremelimumab; assessment of tumor burden changes using mWHO criteria; analysis of tumor-infiltrating lymphocytes (TILs) via immunohistochemistry (IHC); evaluation of tumor mutational burden (TMB) using whole-exome sequencing (WES); and deep biomarker analysis of archived tumor samples using RNA sequencing (RNAseq) and spatial transcriptomics (Xenium), with a specific focus on the expression patterns of IFIT1B and VSTM5 and their association with CD8+ T cell signaling pathways.

Key Conclusions and Perspectives

  • The combination therapy demonstrated preliminary efficacy in BRCA-mutated recurrent ovarian cancer, with an overall response rate (ORR) of 32.7% and a disease control rate (DCR) of 47.7%, with sustained benefits observed in some patients resistant to PARP inhibitors.
  • Regarding safety, 57% of patients experienced grade 3-4 non-hematologic toxicities, primarily associated with Tremelimumab-related immune-related adverse events (irAEs), suggesting the need to optimize dosing regimens to balance efficacy and toxicity.
  • Exploratory biomarker analysis revealed that low expression of IFIT1B and low expression of VSTM5 were strongly correlated with clinical benefit and significantly prolonged progression-free survival (PFS). Notably, the median PFS in the low VSTM5 expression group was significantly superior to that in the high expression group (8.1 months vs. 2.6 months).
  • Spatial transcriptomics analysis revealed that CD8+ T cells in VSTM5-high tumors exhibited significant Type II interferon signaling output, whereas tumor cells in VSTM5-low tumors were more sensitive to FASLG signaling, suggesting that VSTM5 may serve as a key indicator reflecting the immune status of the tumor microenvironment.
  • The study found no significant correlation between PD-L1 expression, TMB, or CD8+ TIL scores and efficacy, indicating that the mechanism of action of CTLA-4 combined with PARP inhibitors may be independent of the traditional PD-1/PD-L1 pathway.

Research Significance and Prospects

These findings offer important guidance for drug development, suggesting that CTLA-4 inhibitors may be an effective strategy to overcome PARP inhibitor resistance, provided they are combined with specific biomarkers for patient stratification. For clinical monitoring, IFIT1B and VSTM5 hold promise as novel biomarkers for predicting responses to immunotherapy, guiding personalized dosing. In terms of disease modeling, the study underscores the importance of using spatial transcriptomics to resolve intercellular communication within the tumor microenvironment (e.g., IFN-γ signaling), providing new targets and validation pathways for developing combination immunotherapies targeting BRCA-mutated tumors in the future.

 

 

Conclusion

This study provides new evidence-based medicine for the treatment of recurrent BRCA-mutated ovarian cancer. Although the combination regimen did not meet the pre-specified primary endpoint, the durable responses observed in the highly pre-treated population highlight the clinical potential of the synergistic effect between CTLA-4 and PARP inhibitors. The study not only validates the feasibility of this combination strategy in overcoming the immunosuppressive microenvironment but, more critically, identifies the value of IFIT1B and VSTM5 as predictive biomarkers. From a translational perspective, these findings lay a solid foundation for future precise screening of benefiting patients and optimization of dosing strategies to reduce immune-related toxicity, with the potential to improve long-term survival outcomes for ovarian cancer patients and advance the establishment of personalized combination immunotherapy regimens.

 

Reference:
Sarah F Adams, Phyllis A Gimotty, Teresa L Rutledge, Olivier Rixe, and Carolyn Y Muller. Olaparib plus tremelimumab in women with recurrent ovarian cancer and a germline BRCA1 or BRCA2 mutation: a phase I/II study. Nature Communications.
Chai-1 is a multimodal molecular structure prediction foundation model, focusing on accurate 3D structure prediction of biomolecules. It achieves state-of-the-art performance in drug discovery and biomolecular interaction studies. Its core value lies in using deep learning techniques to decode the folded structures and interaction mechanisms of biomolecules, providing critical support for targeted drug design and protein function studies.